BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Apatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Apatinib\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07770113-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Apatinib: Phase 2 readout est. (NCT07770113)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Random\, Non-controlled\, Open Cl
 inical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel 
 ± Adebrelimab in Treating Advanced Second-line Gastric Cancer\nEstimated 
 primary completion: 30 November 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07770113
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06454578-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06454578)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adjuvant
  Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recur
 rence After Curative Resection\nEstimated primary completion: December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06454578
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06538935-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06538935)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: SBRT Com
 bined With Adbelimumab and Apatinib for Perioperative and Conversion Thera
 py of Hepatocellular Carcinoma\nEstimated primary completion: December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06538935
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749730-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06749730)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Adebrelimab Combined with Apatinib 
 and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable B
 iliary Tract Carcinoma\nEstimated primary completion: December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06749730
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06576973-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06576973)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Adbelimumab Combined With Chemother
 apy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carc
 inoma\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06576973
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208347-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT04208347)
DESCRIPTION:Apatinib\, phase 2/3.\nStudy: Perioperative Treatment of Combin
 ed SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04208347
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483282-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Apatinib: Phase 2 readout est. (NCT06483282)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Study of Adebrelimab Combined Wit
 h Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker
  Analysis in Limited-stage Small Cell Lung Cancer\nEstimated primary compl
 etion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06483282
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139095-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Apatinib: Phase 2 readout est. (NCT05139095)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Camrelizumab Plus Apatinib in Patie
 nts With High-risk Gestational Trophoblastic Neoplasia\nEstimated primary 
 completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05139095
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062837-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT05062837)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Hepate
 ctomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05062837
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06831175-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06831175)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Phase II Study of PD-1 Inhibitor Co
 mbined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cor
 tical Carcinoma\nEstimated primary completion: 31 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06831175
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06099821-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06099821)
DESCRIPTION:Apatinib\, phase 2.\nStudy: KN046 Plus Regorafenib or Apatinib 
 in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06099821
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06759090-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Apatinib: Phase 2 readout est. (NCT06759090)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Metronomic Capecitabine with Camrel
 izumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer\n
 Estimated primary completion: 15 January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06759090
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745193-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Apatinib: Phase 2 readout est. (NCT06745193)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Prospective\, Randomized\, Open\,
  Phase II Clinical Study of Chidamide in Combination with Camrelizumab and
  Apatinib for Advanced Esophageal Cancer\nEstimated primary completion: 1 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6745193
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07031154-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Apatinib: Phase 2 readout est. (NCT07031154)
DESCRIPTION:Apatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Sing
 le-arm\, Multicenter\, Prospective Clinical Study of Adebrelimab Combined 
 With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cance
 r\nEstimated primary completion: 1 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07031154
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06447623-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Apatinib: Phase 3 readout est. (NCT06447623)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Apatinib Combined With cdk4/6i in F
 irst-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer\nEstimated pr
 imary completion: 1 February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06447623
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06296563-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Apatinib: Phase 2 readout est. (NCT06296563)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Perioperative Treatment of Resectab
 le Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and
  Apatinib and HAIC\nEstimated primary completion: 1 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06296563
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479732-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270305
DTEND;VALUE=DATE:20270306
SUMMARY:Apatinib: Phase 1/2 readout est. (NCT07479732)
DESCRIPTION:Apatinib\, phase 1/2.\nStudy: Apatinib Combined With Liposomal 
 Irinotecan for Refractory or Metastatic Osteosarcoma\nEstimated primary co
 mpletion: 5 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07479732
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280508-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Apatinib: Phase 2 readout est. (NCT06280508)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Chemotherapy Combined With Adebreli
 mab and Apatinib as the Perioperative Treatment in Patients With Biliary T
 ract Cancer\nEstimated primary completion: 31 March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06280508
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06360042-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Apatinib: Phase 2 readout est. (NCT06360042)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Anti-PD-
 1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for U
 nresectable HCC\nEstimated primary completion: 31 March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06360042
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618546-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Apatinib: Phase na readout est. (NCT07618546)
DESCRIPTION:Apatinib\, phase na\, Hepatocellular Carcinoma.\nStudy: A Multi
 center\, Randomized\, Open-label\, Controlled Study of HAIC Combined With 
 Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectab
 le Hepatocellular Carcinoma With High-risk Recurrence Factors\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07618546
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537505-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Apatinib: Phase 2 readout est. (NCT06537505)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Study of Microwave Ablation Combi
 ned With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid 
 Tumors\nEstimated primary completion: 1 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06537505
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385873-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Apatinib: Phase 2 readout est. (NCT06385873)
DESCRIPTION:Apatinib\, phase 2.\nStudy: RC48 Combined With Adebrelimab\, Ap
 atinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer\n
 Estimated primary completion: 1 May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06385873
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973330-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Apatinib: Phase 2 readout est. (NCT06973330)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Sintilimab Plus Apatinib and SOX as
  First-line Treatment in Patients With AFP Gastric or Gastroesophageal Jun
 ction Adenocarcinoma\nEstimated primary completion: 1 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06973330
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192848-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Apatinib: Phase 2 readout est. (NCT07192848)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adebreli
 mab + Apatinib in Advanced HCC Post-Systemic Therapy\nEstimated primary co
 mpletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07192848
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925516-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Apatinib: Phase 2 readout est. (NCT06925516)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Trial of Apatinib and Adebrelimab
  in Combination With Chemotherapy in Patients With Unresectable ICC\nEstim
 ated primary completion: 1 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06925516
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07033819-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Apatinib: Phase 2 readout est. (NCT07033819)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Neoadjuvant Treatment of Ovarian Ca
 ncer With Fuzuloparib in Combination With Apatinib\nEstimated primary comp
 letion: 20 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07033819
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07135544-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Apatinib: Phase 2 readout est. (NCT07135544)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Single-arm\, Multicenter\, Explor
 atory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherap
 y for Initially Unresectable Biliary Tract Cancer\nEstimated primary compl
 etion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07135544
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682272-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Apatinib: Phase 2 readout est. (NCT07682272)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Trial 
 of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatm
 ent of Resectable Hepatocellular Carcinoma\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07682
 272
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294664-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Apatinib: Phase 2 readout est. (NCT07294664)
DESCRIPTION:Apatinib\, phase 2.\nStudy: PDL1/TGFβ In Combination With SHR2
 554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Can
 cer\nEstimated primary completion: 15 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07294664
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786312-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270725
DTEND;VALUE=DATE:20270726
SUMMARY:Apatinib: Phase 2 readout est. (NCT06786312)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Single-arm\, Multicenter\, Prospe
 ctive Phase II Clinical Study of Apatinib in Combination With Adebrelimab 
 and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Ca
 ncer\nEstimated primary completion: 25 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06786312
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03219593-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Apatinib: Phase 2 readout est. (NCT03219593)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Apatinib as the First-Line Therapy 
 in Elderly Locally Advanced or Metastatic Gastric Cancer\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03219593
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105748-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Apatinib: Phase 2 readout est. (NCT07105748)
DESCRIPTION:Apatinib\, phase 2.\nStudy: HAIC Combined With Camrelizumab Plu
 s Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CC
 A)\nEstimated primary completion: 1 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07105748
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314203-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:Apatinib: Phase 3 readout est. (NCT07314203)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Clinical Efficacy of Adebrelimab Wi
 th or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Adv
 anced Gastric Cancer\nEstimated primary completion: 25 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07314203
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05905887-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Apatinib: Phase 2 readout est. (NCT05905887)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Rivoceranib Plus Paclitaxel in Pati
 ents With Gastrointestinal Stromal Tumor\nEstimated primary completion: 31
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 905887
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03020979-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Apatinib: Phase 2 readout est. (NCT03020979)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Clinical Trial With Apatinib for 
 Subjects With Refractory Malignant Ascites\nEstimated primary completion: 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apati
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03020979
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05192798-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Apatinib: Phase 2 readout est. (NCT05192798)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Albumin-Bound Paclitaxel Combined W
 ith Antiangiogenic Agents in First-line Treatment of Relapsed or Metastati
 c TNBC\nEstimated primary completion: 10 September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05192798
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749691-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06749691)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Liposomal Irinotecan and Apatinib i
 n ES-SCLC\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06749691
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893887-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Apatinib: Phase na readout est. (NCT06893887)
DESCRIPTION:Apatinib\, phase na\, Hepatocellular Carcinoma.\nStudy: Individ
 ualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma\nEst
 imated primary completion: 15 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06893887
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334483-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Apatinib: Phase 2 readout est. (NCT07334483)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Study of Yttrium [90Y] Microspher
 e Injection in Combination With Targeted Immunotherapy in the Treatment of
  HCC\nEstimated primary completion: 30 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07334483
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773363-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Apatinib: Phase 2 readout est. (NCT07773363)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Retlirafusp Alfa Plus Apatinib and 
 Chemotherapy as Second-Line Treatment for Pancreatic Cancer\nEstimated pri
 mary completion: 30 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07773363
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764368-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT06764368)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Phase II Study of Adebrelimab\, Che
 motherapy\, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06764368
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154082-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07154082)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Apatinib
  Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for H
 epatocellular Carcinoma\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07154082
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07236528-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07236528)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Combination of Carilizumab\, Apatin
 ib\, and Radiotherapy for Advanced Mucosal Melanoma\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07236528
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314372-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07314372)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: FAD Subt
 ype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07314372
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Fudan University Shanghai Cancer Ce
 nter Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Apatinib\, phase 2/3.\nStudy: Precision Medicine for Immunother
 apy-Resistant Advanced Esophageal Cancer\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apati
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07653451
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925243-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase 3 readout est. (NCT06925243)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Neoadjuvant Apatinib Combined With 
 Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined Wi
 th Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastr
 oesophageal Junction Adenocarcinoma\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06925
 243
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371871-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Apatinib: Phase na readout est. (NCT07371871)
DESCRIPTION:Apatinib\, phase na.\nStudy: A Prospective\, Single-arm\, Explo
 ratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as
  Third-line Therapy for Advanced Gastric Cancer\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07371871
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311408-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Apatinib: Phase 2 readout est. (NCT07311408)
DESCRIPTION:Apatinib\, phase 2.\nStudy: SHR-1701 + Rivoceranib (± SHR-2554
 ) in Advanced GC After First-Line Immunotherapy Failure\nEstimated primary
  completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07311408
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324473-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Apatinib: Phase 2 readout est. (NCT07324473)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ivarmaci
 tinib Combined With Camrelizumab and Apatinib for Unresectable Advanced He
 patocellular Carcinoma With Acquired Resistance to Immune Checkpoint Thera
 py: A Single-Arm Exploratory Clinical Study\nEstimated primary completion:
  1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07324473
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353684-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Apatinib: Phase 2 readout est. (NCT07353684)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Adebrelimab Plus Apatinib Combined 
 With SOX Regimen as Conversion Therapy for Gastric Cancer\nEstimated prima
 ry completion: 1 February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07353684
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796803-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT06796803)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Camrel
 izumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherap
 y (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular C
 arcinoma(HCC)\nEstimated primary completion: 20 February 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06796803
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339619-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Apatinib: Phase 2 readout est. (NCT06339619)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Combination Immunotherapy of Adebre
 limab With Apatinib and Tegafur\, Gimeracil and Oteracil Potassium Capsule
 s for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma\nEs
 timated primary completion: 1 March 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06339619
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687433-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280529
DTEND;VALUE=DATE:20280530
SUMMARY:Apatinib: Phase 2 readout est. (NCT07687433)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Long-Course Concurrent Chemoradioth
 erapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Adv
 anced/Low-Lying Rectal Cancer Requiring Sphincter Preservation\nEstimated 
 primary completion: 29 May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07687433
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464756-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Apatinib: Phase 2 readout est. (NCT07464756)
DESCRIPTION:Apatinib\, phase 2.\nStudy: SHR-1701 With or Without Apatinib i
 n Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer\
 nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07464756
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749859-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Apatinib: Phase 2 readout est. (NCT07749859)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: SHR-1701
  Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Adv
 anced Hepatocellular Carcinoma\nEstimated primary completion: July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07749859
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Apatinib: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Precision Treatment of Recurrent/Me
 tastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstimated pr
 imary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172205-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Apatinib: Phase 3 readout est. (NCT06172205)
DESCRIPTION:Apatinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Infusion
 al FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab 
 and Apatinib for Advanced HCC\nEstimated primary completion: 31 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06172205
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773156-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Apatinib: Phase 2 readout est. (NCT06773156)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Adjuvant Adebrelimab Plus Apatinib 
 After Chemoradiation in Limited-Stage Small Cell Lung Cancer\nEstimated pr
 imary completion: 1 August 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06773156
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803539-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT04803539)
DESCRIPTION:Apatinib\, phase 2/3.\nStudy: A Prospective\, Phase II Trial Us
 ing ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemothe
 rapy in TNBC\nEstimated primary completion: 1 September 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04803539
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357532-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280926
DTEND;VALUE=DATE:20280927
SUMMARY:Apatinib: Phase 2 readout est. (NCT07357532)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Exploration of Treatment Strategies
  After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD\nEstimated p
 rimary completion: 26 September 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07357532
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874425-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07874425)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Retlirafusp Alfa Combined With Zepr
 umetostat\, Apatinib\, and Chemotherapy as First-Line Treatment for Metast
 atic GC/GEJC\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07874425
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569679-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Apatinib: Phase 2 readout est. (NCT07569679)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Alternating HAIC and Systemic Chemo
 therapy With or Without Adebrelimab and Apatinib for Unresectable Biliary 
 Tract Cancer\nEstimated primary completion: 30 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07569679
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610629-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07610629)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Retlirafusp Alfa Combined With Apat
 inib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesop
 hageal Junction Cancer\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07610629
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589244-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT07589244)
DESCRIPTION:Apatinib\, phase 2/3.\nStudy: A Study of VRT106\, Combined With
  Camrelizumab\, and Apatinib for Advanced HCC\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07589244
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889688-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Apatinib: Phase 3 readout est. (NCT06889688)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Phase III Trial of Camrelizumab+Apa
 tinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Nega
 tive Breast Cancer\nEstimated primary completion: 31 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06889688
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790419-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Apatinib: Phase 4 readout est. (NCT07790419)
DESCRIPTION:Apatinib\, phase 4\, Hepatocellular Carcinoma.\nStudy: A Prospe
 ctive\, Single-Arm\, Open-Label Clinical Study of the Efficacy and Safety 
 of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy a
 nd a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinom
 a and Microvascular Invasion\nEstimated primary completion: 31 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07790419
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802184-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Apatinib: Phase 1/2 readout est. (NCT07802184)
DESCRIPTION:Apatinib\, phase 1/2.\nStudy: GnP Combined With SHR-1701 and Ap
 atinib as First-Line Treatment for Metastatic PDAC\nEstimated primary comp
 letion: 1 January 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07802184
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06181032-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Apatinib: Phase 1 readout est. (NCT06181032)
DESCRIPTION:Apatinib\, phase 1.\nStudy: A Study of Adebrelimab in Combinati
 on With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies\n
 Estimated primary completion: 23 February 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06181032
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771154-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Apatinib: Phase 2 readout est. (NCT06771154)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Adebrelimab Plus Carboplatin/Paclit
 axel Followed by Adebelizumab with or Without Apatinib in the Treatment of
  Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter\
 , Randomized\, Controlled\, Open-Label Clinical Trial\nEstimated primary c
 ompletion: 1 April 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/apatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06771154
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Apatinib: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Establishment of Precision Targeted
  Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular S
 ubtyping\nEstimated primary completion: 1 August 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07267806-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Apatinib: Phase 3 readout est. (NCT07267806)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Camrelizumab and Apatinib With or W
 ithout FOLFOX Chemotherapy for Advanced HCC\nEstimated primary completion:
  October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7267806
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07587034-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Apatinib: Phase 1/2 readout est. (NCT07587034)
DESCRIPTION:Apatinib\, phase 1/2.\nStudy: HAIC-TACE Plus Apatinib and Camre
 lizumab for Liver Cancer\nEstimated primary completion: December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07587034
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07907354-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Apatinib: Phase 2 readout est. (NCT07907354)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Low-Dose Apatinib Plus Chemotherapy
  in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer\nEsti
 mated primary completion: 30 December 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07907354
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904442-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07904442)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Application of Intraperitoneal Hype
 rthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal M
 etastasis\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07904442
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934927-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Apatinib: Phase 2 readout est. (NCT07934927)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Phase II Study of Nab-Paclitaxel 
 Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Muco
 sal Melanoma\nEstimated primary completion: 31 December 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07934927
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02485015-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Apatinib: Phase 2 readout est. (NCT02485015)
DESCRIPTION:Apatinib\, phase 2.\nStudy: The Study of Apatinib Plus CIK as t
 he Third Line Therapy for Patients With Advanced Gastric Cancer\nEstimated
  primary completion: June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT02485015
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02493582-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Apatinib: Phase 2 readout est. (NCT02493582)
DESCRIPTION:Apatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The St
 udy of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adeno
 carcinoma Patients With Wild-Type EGFR\nEstimated primary completion: July
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT02493582
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684040-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Apatinib: Phase 2 readout est. (NCT07684040)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A Study of Combination Therapy in P
 atients With Resectable Liver Cancer\nEstimated primary completion: 1 July
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07684040
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739317-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Apatinib: Phase 2/3 readout est. (NCT06739317)
DESCRIPTION:Apatinib\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: SBRT C
 ombined with Camrelizumab and Apatinib for Conversion Therapy in Patients 
 with Unresectable Hepatocellular Carcinoma.\nEstimated primary completion:
  31 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ap
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06739317
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06255392-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Apatinib: Phase 3 readout est. (NCT06255392)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Randomized\, Open\, Controlled\, Mu
 lticenter Phase III Clinical Study of Fluzoparib in Combination With Apati
 nib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negati
 ve Advanced Breast Cancer\nEstimated primary completion: March 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06255392
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371910-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Apatinib: Phase 3 readout est. (NCT07371910)
DESCRIPTION:Apatinib\, phase 3.\nStudy: Fluorizoparib Plus Apatinib Versus 
 Chemotherapy in HRD-positive\, HER2-negative Advanced Breast Cancer\nEstim
 ated primary completion: March 2031. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/apatinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07371910
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992336-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20310410
DTEND;VALUE=DATE:20310411
SUMMARY:Apatinib: Phase 2 readout est. (NCT06992336)
DESCRIPTION:Apatinib\, phase 2.\nStudy: Circulating Tumor DNA Guided Boost 
 Therapy in Early Triple Negative Breast Patients With Residual Disease Aft
 er Neoadjuvant Therapy\nEstimated primary completion: 10 April 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06992336
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934331-2014@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20310806
DTEND;VALUE=DATE:20310807
SUMMARY:Apatinib: Phase 2 readout est. (NCT05934331)
DESCRIPTION:Apatinib\, phase 2.\nStudy: A LM-302 Combination With Other Ant
 i-Tumor Therapies Phase ll Study\nEstimated primary completion: 6 August 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05934331
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
